US 10335382
Use of hydrogen sulfide synthesis inhibitors for cancer therapy
granted A61KA61K31/195A61K31/22
Quick answer
US patent 10335382 (Use of hydrogen sulfide synthesis inhibitors for cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 1
- CPC classes
- A61K, A61K31/195, A61K31/22, A61K31/221, A61K31/222